For lung cancer patients harboring a secondary mutation in EGFR that abrogates EGFR TKI affinity or binding, such as exon 20 insertion, duplication and the T790M substitution, the development of novel EGFR TKIs are needed to more effectively target mutant EGFR. The gene discussed is EGFR; the disease is lung cancer.